1 Embleton, NE, Pang, N & Cooke, RJ (2001) Postnatal malnutrition and growth retardation: an inevitable consequence of current recommendations in preterm infants? Pediatrics 107, 270–273.
2 Carlson, SJ (1999) Actual nutrient intakes of extremely low-birthweight infants. In Nutrition of the Very Low Birthweight Infant, pp. 221–228 [Ziegler, EE, Lucas, A and Moro, GE, editors]. Philadelphia, PA: Lippincott Williams & Wilkins.
3 Ehrenkranz, RA, Younes, N, Lemons, JA, et al. (1999) Longitudinal growth of hospitalized very low birth weight infants. Pediatrics 104, 280–289.
4 Fenton, TR, McMillan, DD & Sauve, RS (1990) Nutrition and growth analysis of very low birth weight infants. Pediatrics 86, 378–383.
5 Franz, AR, Pohlandt, F, Bode, H, et al. (2009) Intrauterine, early neonatal, and postdischarge growth and neurodevelopmental outcome at 5·4 years in extremely preterm infants after intensive neonatal nutritional support. Pediatrics 123, e101–e109.
6 Tan, M, Abernethy, L & Cooke, R (2008) Improving head growth in preterm infants – a randomised controlled trial II: MRI and developmental outcomes in the first year. Arch Dis Child Fetal Neonatal Ed 93, F342–F346.
7 Ehrenkranz, RA (2007) Early, aggressive nutritional management for very low birth weight infants: what is the evidence? Semin Perinatol 31, 48–55.
8 Latal-Hajnal, B, von Siebenthal, K, Kovari, H, et al. (2003) Postnatal growth in VLBW infants: significant association with neurodevelopmental outcome. [see comment]. J Pediatr 143, 163–170.
9 Carlson, SE, Werkman, SH & Tolley, EA (1996) Effect of long-chain n-3 fatty acid supplementation on visual acuity and growth of preterm infants with and without bronchopulmonary dysplasia. Am J Clin Nutr 63, 687–697.
10 Ryan, AS, Montalto, MB, Groh-Wargo, S, et al. (1999) Effect of DHA-containing formula on growth of preterm infants to 59 weeks postmenstrual age. Am J Hum Biol 11, 457–467.
11 Carlson, SE, Cooke, RJ, Werkman, SH, et al. (1992) First year growth of preterm infants fed standard compared to marine oil n-3 supplemented formula. Lipids 27, 901–907.
12 Carlson, SE, Werkman, SH, Peeples, JM, et al. (1993) Arachidonic acid status correlates with first year growth in preterm infants. Proc Natl Acad Sci U S A 90, 1073–1077.
13 Clandinin, MT, Van Aerde, JE, Merkel, KL, et al. (2005) Growth and development of preterm infants fed infant formulas containing docosahexaenoic acid and arachidonic acid. J Pediatr 146, 461–468.
14 Innis, SM, Adamkin, DH, Hall, RT, et al. (2002) Docosahexaenoic acid and arachidonic acid enhance growth with no adverse effects in preterm infants fed formula. J Pediatr 140, 547–554.
15 O'Connor, DL, Hall, R, Adamkin, D, et al. (2001) Growth and development in preterm infants fed long-chain polyunsaturated fatty acids: a prospective, randomized controlled trial. Pediatrics 108, 359–371.
16 Vanderhoof, J, Gross, S, Hegyi, T, et al. (1999) Evaluation of a long-chain polyunsaturated fatty acid supplemented formula on growth, tolerance, and plasma lipids in preterm infants up to 48 weeks postconceptional age. J Pediatr Gastroenterol Nutr 29, 318–326.
17 Clandinin, MT, Van Aerde, JE, Parrott, A, et al. (1997) Assessment of the efficacious dose of arachidonic and docosahexaenoic acids in preterm infant formulas: fatty acid composition of erythrocytemembrane lipids. Pediatr Res 42, 819–825.
18 Stier, C, Hess, M, Watzer, B, et al. (1997) Prostanoid formation during feeding of a preterm formula with long-chain polyunsaturated fatty acids in healthy preterm infants during the first weeks of life. Pediatr Res 42, 509–513.
19 Fewtrell, MS, Morley, R, Abbott, RA, et al. (2002) Double-blind, randomized trial of long-chain polyunsaturated fatty acid supplementation in formula fed to preterm infants. [see comment]. Pediatrics 110, 73–82.
21 Rosenfeld, E, Beyerlein, A, Hadders-Algra, M, et al. (2009) IPD meta-analysis shows no effect of LC-PUFA supplementation on infant growth at 18 months. Acta Paediatrica 98, 91–97.
22 Makrides, M, Gibson, RA, McPhee, AJ, et al. (2009) Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: a randomized controlled trial. JAMA 301, 175–182.
23 WHO Multicentre Growth Reference Study Group (2006) WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl 450, 76–85.
25 Kan, E, Roberts, G, Anderson, PJ, et al. (2008) The association of growth impairment with neurodevelopmental outcome at eight years of age in very preterm children. Early Hum Dev 84, 409–416.
26 Ehrenkranz, RA, Dusick, AM, Vohr, BR, et al. (2006) Growth in the neonatal intensive care unit influences neurodevelopmental and growth outcomes of extremely low birth weight infants. Pediatrics 117, 1253–1261.
27 Smithers, LG, Gibson, RA, McPhee, A, et al. (2008) Effect of two doses of docosahexaenoic acid (DHA) in the diet of preterm infants on infant fatty acid status: results from the DINO trial. Prostaglandins Leukot Essent Fatty Acids 79, 141–146.
28 Gibson, RA, Neumann, MA & Makrides, M (1997) Effect of increasing breast milk docosahexaenoic acid on plasma and erythrocyte phospholipid fatty acids and neural indices of exclusively breast fed infants. Eur J Clin Nutr 51, 578–584.